Science Explorer Interactive view Map
Company · Uden · Netherlands

Hycult Biotech (Netherlands)

hycultbiotech.comROR OpenAlex
Research works
17
▲ 31% vs 2013–17
Citations
329
18.8 per fractional work
Top-10% rate
39.2%
record average 16.5%
Open access
59%
world 28%

Not ranked overall: Hycult Biotech (Netherlands) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 4.56× its world share, 2 worksBiochemistry, Geneti…Immunology and Microbiology: 14.84× its world share, 1 worksImmunology and Micro…Neuroscience: 0.79× its world share, 0 worksNeuroscienceChemistry: 0.81× its world share, 0 worksChemistryMaterials Science: 0.29× its world share, 0 worksMaterials ScienceMedicine: 2.90× its world share, 4 worksMedicineBusiness, Management and Accounting: 0.16× its world share, 0 worksBusiness, Management…Economics, Econometrics and Finance: 0.40× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 14.8×. Every wedge is a field page.

Which research topics does Hycult Biotech (Netherlands) publish most on?

By volume in 2022–2025: Complement system in diseases, Clusterin in disease pathology, COVID-19 Clinical Research Studies and Ubiquitin and proteasome pathways.

Complement system in dis…1Complement system in diseases: 1 fractional worksClusterin in disease pathology: 0 fractional worksCOVID-19 Clinical Research Studies: 0 fractional worksUbiquitin and proteasome pathways: 0 fractional worksBlood groups and transfusion: 0 fractional worksLong-Term Effects of COVID-19: 0 fractional worksRetinoids in leukemia an…0Retinoids in leukemia and cellular processes: 0 fractional worksCancer, Hypoxia, and Metabolism: 0 fractional worksSARS-CoV-2 and COVID-19 Research: 0 fractional worksTelomeres, Telomerase, and Senescence: 0 fractional works
ImmunologyOncologyInfectious DiseasesMolecular Biology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Complement system in diseases Immunology 1 works
  2. 2 Clusterin in disease pathology Oncology 0 works
  3. 3 COVID-19 Clinical Research Studies Infectious Diseases 0 works
  4. 4 Ubiquitin and proteasome pathways Molecular Biology 0 works
  5. 5 Blood groups and transfusion Hematology 0 works
  6. 6 Long-Term Effects of COVID-19 Neurology 0 works
  7. 7 Retinoids in leukemia and cellular processes Molecular Biology 0 works
  8. 8 Cancer, Hypoxia, and Metabolism Cancer Research 0 works
  9. 9 SARS-CoV-2 and COVID-19 Research Infectious Diseases 0 works
  10. 10 Telomeres, Telomerase, and Senescence Physiology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available58.8%not open41.2%

World: 28% of research is openly available.

with international co-authors59.5%domestic only40.5%

World: 19% is written across borders.

How has Hycult Biotech (Netherlands)'s research output changed?

Output in 2018–2022 was 31% higher than in 2013–2017.

200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Uden

All research institutions in Uden

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.